Nuclear medicine is expected to make major advances in cancer diagnosis and therapy;
tumor-targeted radiopharmaceuticals preferentially eradicate tumors while causing minimal …

Neuroendocrine tumors have shown rising incidence mainly due to higher clinical
awareness and better diagnostic tools over the last 30 years. Functional imaging of …

To date, empirical literature has generally been considered lacking in relation to
neuroendocrine carcinomas (NECs), the highly malignant subgroup of neuroendocrine …

Aim One of the primary prerequisites for peptide receptor radionuclide therapy (PRRT) in
patients with neuroendocrine tumors (NET) is the presence of somatostatin receptors …

Theranostics of neuroendocrine neoplasms (NENs) based on molecular imaging using
receptor positron emission tomography/computed tomography (PET/CT) with 68Ga-labeled …

Abstract Purpose PET with 68 Ga-DOTATOC allows for imaging and quantitative
assessment of somatostatin receptor expression in neuroendocrine tumors (NET). The aim …

Progress in the diagnostics and therapy of gastro-entero-pancreatic (GEP) neuroendocrine
neoplasms (NEN), the published results of new randomised clinical trials, and the new …

Over the past several years, Positron Emission Tomography (PET) imaging agents labeled
with 68Gallium (68Ga) have undergone a significant increase in clinical utilization. 68Ga is …

Background Radiotheragnostics makes use of the same molecular targeting vectors, labeled
either with a diagnostic or therapeutic radionuclide, ideally of the same chemical element …

Purpose To determine the value of 68 Ga-DOTA-TOC and 18 F-FDG PET/CT for initial and
follow-up evaluation of patients with neuroendocrine tumour (NET) treated with peptide …